Inflammatory skin diseases such as atopic dermatitis (AD) and psoriasis are considered major public issues with increasing prevalence due to the rapid industrialization of modern society [1, 2]. These diseases are more frequent in industrialized countries than in developing countries with higher prevalence in urban areas compared to rural areas [1,3]. Rapid industrialization has increased production of carbon dioxide and various exhaust gases, resulting in many forms of air pollution and high-allergen environments. Allergic diseases including AD are more closely related to these environmental changes. The elevated carbon dioxide concentrations and temperatures in cities enhance the production and allergenicity of pollen, one of the well-known plant allergens. In addition, diesel exhaust particles have been reported to directly induce histamine release from mast cells (MCs) with the aggravation of allergic symptoms.

The symptoms of these diseases can deteriorate the quality of life of patients as a result of an impaired skin barrier, itch, insomnia, and social stigma over a long period of time. However, treatments for these disorders are limited with few approved therapeutic options for patients with moderate-to-severe symptoms who are unresponsive to topical steroids or systemic immunosuppressants. Although biologics that target a specific cytokine or mediator seem to be effective, those drugs should be treated through multiple administration to exert sufficient efficacy and their safety should be further confirmed by long-term follow-up study.

Why mesenchymal stem cells treatment?

Mesenchymal stem cells (MSCs), the major stem cells in the field of cell therapy, have been used in the clinic for more than 10 years and proven to be safe and effective for the treatment of various intractable autoimmune and inflammatory disorders because of their distinct immunomodulatory properties.

MSC have been shown to possess a strong ability to improve tissue damage in response to skin injury, by contributing to collagen deposition, wound contraction, angiogenesis, regeneration of skin appendages, and enhanced growth of epidermal cells [11]. A small population of umbilical cord-derived MSCs coexpresses the mesenchymal marker vimentin and the epithelial marker pan-cytokeratin. MSCs can survive and can adapt more easily to the culture conditions of the skin. The restoration of cutaneous appendages, after a severe skin injury, which is related to the function of the regenerated skin and affects the quality of life, may be an important function of MSCs during skin repair.

Allogeneic stem cells can be administered multiple times over the course of days in uniform dosages, they are immune system privileged, cell rejection is not an issue and Human Leukocyte Antigen (HLA) matching is not necessary.

No need to collect stem cells from the patient’s hip bone or fat under anesthesia, which especially for small children and their parents, can be an unpleasant ordeal.

No need to administer chemotherapy drugs like granulocyte-colony stimulating factor (G-CSF or GCSF) to stimulate the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.


Therapy impact

Results of the therapy always depend on a condition and individual profile. Expected improvements:

  • promote tissue regeneration
  • reduce inflammation
  • thus increasing the quality of life.


Your treatment plan in QR Health Solutions:

Day 1 Examination

- Initial examination by physician/doctor of certain specialization - Familiarization with medical history of patient


Infectious Blood Screening

Anti-aging cosmetological treatment

QR clinic provides repetitive administration of UCD-MSC (stem cells)


Clinical examination, planning of further observation, discharge


Just fill the application and one of our specialists will contact you by e-mail, phone, or any other convenient way for you. We will be happy to answer all your questions and provide the necessary information.